Dr. Whelan Discusses the MA.20 Trial's Survival Findings

Timothy J. Whelan, BM, BCh
Published: Friday, Jul 08, 2011



Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, discusses the various survival benefits found in the NCIC-CTG MA.20 intergroup phase III trial that randomized 1832 breast cancer patients to receive either whole-breast irradiation (WBI) or WBI plus regional nodal irradiation (RNI). Patients that received both RNI and WBI saw a disease-free survival of nearly 90% but failed to meet the primary endpoint of overall survival.


Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, discusses the various survival benefits found in the NCIC-CTG MA.20 intergroup phase III trial that randomized 1832 breast cancer patients to receive either whole-breast irradiation (WBI) or WBI plus regional nodal irradiation (RNI). Patients that received both RNI and WBI saw a disease-free survival of nearly 90% but failed to meet the primary endpoint of overall survival.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x